Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Updated Mechanisms Underlying Sickle Cell Disease-Associated Pain
source: Translational Perioperative and Pain Medicine
year: 2015
authors: Lutz B, Meiler SE, Bekker A, Tao YX
summary/abstract:Sickle cell disease (SCD) is one of the most common severe genetic diseases around the world. A majority of SCD patients experience intense pain, leading to hospitalization, and poor quality of life. Opioids form the bedrock of pain management, but their long-term use is associated with severe side effects including hyperalgesia, tolerance and addiction.
Recently, excellent research has shown some new potential mechanisms that underlie SCD-associated pain. This review focused on how transient receptor potential vanilloid 1, endothelin-1/endothelin type A receptor, and cannabinoid receptors contributed to the pathophysiology of SCD-associated pain. Understanding these mechanisms may open a new avenue in managing SCD-associated pain and improving quality of life for SCD patients.
organization: The State University of New Jersey, USA; Georgia Regents University, USADOI: 10.1016/j.neulet.2019.134471
read more
+myBinderRelated Content
-
The Association Between Timely Opioid Administration and Hospitalization in Children With Sickle Cell Disease Presen...Objective: To evaluate the association ...
-
Medical Marijuana for Sickle Cell Disease: Results of Two Years of Certification in an Adult Sickle Cell CenterBackground: The hallmark of sickle cell ...
-
Improving Quality of Life Through Sickle Cell Research: Marsha J. Treadwell, MDhttps://www.youtube.com/watch?v=DA51AAUH...
-
When Cracking Down On Opioids Means Tougher Access For Sickle Cell PatientsMany people with sickle cell disease wil...
-
Hospitals See No Link Between US Opioid Crisis and Patients’ Use of Treatment, Study ReportsThe U.S. opioid epidemic is not linked t...
-
Jazz’ Journey With Sickle Cellhttps://www.youtube.com/watch?v=OMC5wOyD...
-
Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle ...Global biotherapeutics leader CSL Behrin...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.